Retrospective analysis of outcomes of biosimilar ranibizumab (BSR) in treating cystoid macular oedema (CME) in ischaemic central retinal venous occlusion (CRVO)

Abstract

Objectives: The objective of this study was to understand the efficacy of biosimilar ranibizumab (BSR) in treating cystoid macular oedema in ischaemic central retinal venous occlusion (CRVO) in developing countries like India. Materials and Methods: Data from ten patients diagnosed with ischaemic CRVO were analysed in the form of a central foveal thickness (CFT), visual acuity and pupillary reaction after three doses of intravitreal BSR at the end of 1 month, 3 months and 6 months. Results: There was a significant reduction in CFT after 1, 3 and 6 months post 1st dose of BSR (P < 0.05) with moderately improved visual acuity after 3 and 6 months of post 1st dose of BSR (P < 0.05). Conclusion: BSR has been found to be a low-cost alternative to conventional therapy in treating ischaemic CRVO with macular oedema.